LU85514A1 - Nouveaux esters de polyols,leur preparation et leur utilisation - Google Patents

Nouveaux esters de polyols,leur preparation et leur utilisation Download PDF

Info

Publication number: LU85514A1
Authority: LU; Luxembourg
Prior art keywords: polyol; molecular weight; acid; hydroxy groups; product according
Prior art date: 1983-08-26

Application number

LU85514A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-26

Filing date

1984-08-24

Publication date

1985-04-24

1984-08-24 Application filed by Sandoz Sa filed Critical Sandoz Sa

1985-04-24 Publication of LU85514A1 publication Critical patent/LU85514A1/fr

Links

229920005862 polyol Polymers 0.000 title claims description 86
-1 POLYOL ESTERS Chemical class 0.000 title claims description 55
238000002360 preparation method Methods 0.000 title claims description 10
150000003077 polyols Chemical class 0.000 claims description 41
239000004480 active ingredient Substances 0.000 claims description 37
239000000047 product Substances 0.000 claims description 34
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 31
239000003094 microcapsule Substances 0.000 claims description 28
239000011159 matrix material Substances 0.000 claims description 27
229920000642 polymer Polymers 0.000 claims description 25
239000012730 sustained-release form Substances 0.000 claims description 25
150000002148 esters Chemical class 0.000 claims description 21
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 20
238000000034 method Methods 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 17
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 16
239000002253 acid Substances 0.000 claims description 16
239000008103 glucose Substances 0.000 claims description 16
239000004310 lactic acid Substances 0.000 claims description 16
235000014655 lactic acid Nutrition 0.000 claims description 14
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 13
239000007943 implant Substances 0.000 claims description 12
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical group C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 11
229960002802 bromocriptine Drugs 0.000 claims description 11
239000013543 active substance Substances 0.000 claims description 10
238000013268 sustained release Methods 0.000 claims description 8
ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 7
238000002270 exclusion chromatography Methods 0.000 claims description 6
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 6
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 6
239000003054 catalyst Substances 0.000 claims description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
229930195725 Mannitol Natural products 0.000 claims description 4
125000004122 cyclic group Chemical group 0.000 claims description 4
239000000594 mannitol Substances 0.000 claims description 4
235000010355 mannitol Nutrition 0.000 claims description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
229930091371 Fructose Natural products 0.000 claims description 3
239000005715 Fructose Substances 0.000 claims description 3
JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims description 3
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
239000007795 chemical reaction product Substances 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims description 3
239000000600 sorbitol Substances 0.000 claims description 3
239000000811 xylitol Substances 0.000 claims description 3
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
235000010447 xylitol Nutrition 0.000 claims description 3
229960002675 xylitol Drugs 0.000 claims description 3
150000002596 lactones Chemical class 0.000 claims description 2
150000002772 monosaccharides Chemical class 0.000 claims description 2
238000006116 polymerization reaction Methods 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims 2
238000013265 extended release Methods 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical group CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 21
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 19
238000006243 chemical reaction Methods 0.000 description 12
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 12
230000015556 catabolic process Effects 0.000 description 11
238000006731 degradation reaction Methods 0.000 description 11
239000002904 solvent Substances 0.000 description 11
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
229920000747 poly(lactic acid) Polymers 0.000 description 9
238000003756 stirring Methods 0.000 description 9
238000001914 filtration Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000000338 in vitro Methods 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000002955 isolation Methods 0.000 description 6
238000000746 purification Methods 0.000 description 6
239000000470 constituent Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
XZZXKVYTWCYOQX-UHFFFAOYSA-J octanoate;tin(4+) Chemical group [Sn+4].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O.CCCCCCCC([O-])=O.CCCCCCCC([O-])=O XZZXKVYTWCYOQX-UHFFFAOYSA-J 0.000 description 5
239000001116 FEMA 4028 Substances 0.000 description 4
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
235000011175 beta-cyclodextrine Nutrition 0.000 description 4
229960004853 betadex Drugs 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
229960004958 ketotifen Drugs 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229920000858 Cyclodextrin Polymers 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 3
238000009835 boiling Methods 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
238000004945 emulsification Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
238000002329 infrared spectrum Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000005374 membrane filtration Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
238000005303 weighing Methods 0.000 description 3
JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
102000003946 Prolactin Human genes 0.000 description 2
108010057464 Prolactin Proteins 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
WQZGKKKJIJFFOK-UKLRSMCWSA-N dextrose-2-13c Chemical compound OC[C@H]1OC(O)[13C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-UKLRSMCWSA-N 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
150000003903 lactic acid esters Chemical class 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229940097325 prolactin Drugs 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000005507 spraying Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical group OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
230000002460 anti-migrenic effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
229940045348 brown mixture Drugs 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
238000010908 decantation Methods 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000005375 photometry Methods 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
239000012264 purified product Substances 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Polymers & Plastics (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Polyesters Or Polycarbonates (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU85514A 1983-08-26 1984-08-24 Nouveaux esters de polyols,leur preparation et leur utilisation LU85514A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH467183		1983-08-26
CH4671/83A CH656884A5 (de)	1983-08-26	1983-08-26	Polyolester, deren herstellung und verwendung.

Publications (1)

Publication Number	Publication Date
LU85514A1 true LU85514A1 (fr)	1985-04-24

Family

ID=4280440

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU85514A LU85514A1 (fr)	1983-08-26	1984-08-24	Nouveaux esters de polyols,leur preparation et leur utilisation

Country Status (27)

Country	Link
US (2)	US5922682A (de)
JP (1)	JPH0819226B2 (de)
AT (1)	AT395584B (de)
AU (1)	AU575066B2 (de)
BE (1)	BE900406A (de)
CH (1)	CH656884A5 (de)
CY (1)	CY1556A (de)
DE (1)	DE3430852C2 (de)
DK (1)	DK173556B1 (de)
ES (1)	ES8706750A1 (de)
FR (1)	FR2551072B1 (de)
GB (1)	GB2145422B (de)
GR (1)	GR80184B (de)
HK (1)	HK67390A (de)
HU (1)	HU195426B (de)
IE (1)	IE58818B1 (de)
IL (1)	IL72763A (de)
IT (1)	IT1176629B (de)
LU (1)	LU85514A1 (de)
MY (1)	MY101861A (de)
NL (2)	NL190415C (de)
NZ (1)	NZ209335A (de)
PH (1)	PH23556A (de)
PT (1)	PT79129B (de)
SE (1)	SE462098B (de)
SG (1)	SG53590G (de)
ZA (1)	ZA846634B (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2551756B2 (ja) *	1985-05-07	1996-11-06	武田薬品工業株式会社	ポリオキシカルボン酸エステルおよびその製造法
DE3641692A1 (de) *	1986-12-06	1988-06-09	Boehringer Ingelheim Kg	Katalysatorfreie resorbierbare homopolymere und copolymere
GB8801863D0 (en) *	1988-01-28	1988-02-24	Fulmer Yarsley Ltd	Pharmaceutical formulations with controlled drug release
US5247013A (en) *	1989-01-27	1993-09-21	Mitsui Toatsu Chemicals, Inc.	Biocompatible polyester and production thereof
CA2025893A1 (en) *	1989-01-27	1990-07-28	Hosei Shinoda	Biocompatible polyester and production thereof
HU221294B1 (en) *	1989-07-07	2002-09-28	Novartis Ag	Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5538739A (en) *	1989-07-07	1996-07-23	Sandoz Ltd.	Sustained release formulations of water soluble peptides
PH30995A (en) *	1989-07-07	1997-12-23	Novartis Inc	Sustained release formulations of water soluble peptides.
US6353030B1 (en) *	1990-08-01	2002-03-05	Novartis Ag	Relating to organic compounds
MY108621A (en) *	1990-08-01	1996-10-31	Novartis Ag	Polylactide preparation and purification
US5208316A (en) *	1990-10-01	1993-05-04	Toppan Printing Co., Ltd.	Cyclodextrin polymer and cyclodextrin membrane prepared using said polymer
US5225521A (en) *	1991-12-31	1993-07-06	E. I. Du Pont De Nemours And Company	Star-shaped hydroxyacid polymers
US5247058A (en) *	1992-01-24	1993-09-21	Cargill, Incorporated	Continuous process for manufacture of lactide polymers with controlled optical purity
US5258488A (en) *	1992-01-24	1993-11-02	Cargill, Incorporated	Continuous process for manufacture of lactide polymers with controlled optical purity
US5142023A (en) *	1992-01-24	1992-08-25	Cargill, Incorporated	Continuous process for manufacture of lactide polymers with controlled optical purity
US5247059A (en) *	1992-01-24	1993-09-21	Cargill, Incorporated	Continuous process for the manufacture of a purified lactide from esters of lactic acid
US6326458B1 (en)	1992-01-24	2001-12-04	Cargill, Inc.	Continuous process for the manufacture of lactide and lactide polymers
US6005067A (en) *	1992-01-24	1999-12-21	Cargill Incorporated	Continuous process for manufacture of lactide polymers with controlled optical purity
GB9206736D0 (en) *	1992-03-27	1992-05-13	Sandoz Ltd	Improvements of organic compounds and their use in pharmaceutical compositions
FR2692168B1 (fr) *	1992-06-16	1995-03-24	Centre Nat Rech Scient	Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
FR2692167B1 (fr) *	1992-06-16	1994-09-16	Centre Nat Rech Scient	Préparation et application de nouveaux systèmes colloïdaux nanovésiculaires dispersibles à base de cyclodextrine, sous forme de nanocapsules.
AU4198793A (en) †	1992-07-24	1994-01-27	Takeda Chemical Industries Ltd.	Microparticle preparation and production thereof
US6005068A (en)	1992-10-02	1999-12-21	Cargill Incorporated	Melt-stable amorphous lactide polymer film and process for manufacture thereof
US5338822A (en) *	1992-10-02	1994-08-16	Cargill, Incorporated	Melt-stable lactide polymer composition and process for manufacture thereof
DE69330046T2 (de) *	1992-10-02	2001-11-15	Cargill, Inc.	Schmelzstabiles lactidpolymergewebe und verfahren zu seiner herstellung
NZ256978A (en) *	1992-10-02	1996-05-28	Cargill Inc	Paper product coated with a poly(lactide) composition comprising no more than 5 wt % lactide monomer, the poly(lactide) having a number average mw of 10,000 to 200,000
TW333456B (en)	1992-12-07	1998-06-11	Takeda Pharm Ind Co Ltd	A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
EP0668073B1 (de) *	1994-02-21	1999-04-14	Takeda Chemical Industries, Ltd.	Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
DE4406172C2 (de) *	1994-02-25	2003-10-02	Sanol Arznei Schwarz Gmbh	Polyester
ES2078190B1 (es) *	1994-05-20	1996-08-01	Cusi Lab	Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
US5817728A (en) *	1995-03-16	1998-10-06	Mitsui Chemicals, Inc.	Preparation of degradable copolymers
US5914381A (en) *	1996-09-12	1999-06-22	Mitsui Chemicals, Inc.	Degradable polymer and preparation process of the same
US5916883A (en) *	1996-11-01	1999-06-29	Poly-Med, Inc.	Acylated cyclodextrin derivatives
AR020650A1 (es) *	1998-08-10	2002-05-22	Poly Med Inc	Polimeros fosforilados y conjugados de los mismos
DE19839515B4 (de) *	1998-08-29	2012-02-02	Nanohale Gmbh	Neue pharmazeutische Zubereitung, enthaltend kolloidale Polymer-Wirkstoff-Assoziate, insbesondere auch für mucosale Wirkstoffverabreichung
US6955822B1 (en)	1998-11-02	2005-10-18	Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Of Paris	Lactone bearing absorbable polymers
US6451346B1 (en) *	1998-12-23	2002-09-17	Amgen Inc	Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US8614291B2 (en)	1999-08-10	2013-12-24	Poly-Med, Inc.	Phosphorylated polymers and conjugates thereof
US6461631B1 (en) *	1999-11-16	2002-10-08	Atrix Laboratories, Inc.	Biodegradable polymer composition
ATE466042T1 (de) *	2000-03-08	2010-05-15	Lab Internat Barbados Srl	Kolloidale nanopartikuläre träger enthaltend geladene oder ungeladene wasserlösliche kammpolymere und deren verwendung zur mucosalen applikation
US6616944B2 (en) *	2000-03-08	2003-09-09	Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh	Self-assembling colloidal carriers for protein delivery
CN1269870C (zh) *	2000-08-07	2006-08-16	和光纯药工业株式会社	乳酸聚合物及其制备方法
DE10055742B4 (de) *	2000-11-10	2006-05-11	Schwarz Pharma Ag	Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
DE10111767B4 (de) *	2001-03-12	2005-03-24	Schwarz Pharma Ag	Verfahren zur Herstellung von Polyestern aus Hydroxycarbonsäuren und Polyolen durch Polykondensation
TWI332407B (en) †	2001-06-29	2010-11-01	Takeda Chemical Industries Ltd	Controlled release composition and method of producting the same
GB0122318D0 (en) *	2001-09-14	2001-11-07	Novartis Ag	Organic compounds
BRPI0213564B8 (pt)	2001-10-30	2021-05-25	Novartis Ag	formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
EP2316468A1 (de)	2002-02-22	2011-05-04	Shire LLC	Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
GB0216416D0 (en)	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
US20040097419A1 (en) *	2002-11-19	2004-05-20	Holger Petersen	Organic compounds
US20060089384A1 (en) *	2004-10-25	2006-04-27	Minno George E	Ophthalmic compositions and methods of using the same
CA2585266C (en) *	2004-10-25	2010-10-19	Bausch & Lomb Incorporated	Ophthalmic compositions and methods of using the same
GB2422839B (en)	2005-01-11	2009-06-24	Schlumberger Holdings	Degradable polymers for wellbore fluids and processes
US7794495B2 (en) *	2006-07-17	2010-09-14	Advanced Cardiovascular Systems, Inc.	Controlled degradation of stents
EP2065421B1 (de)	2006-09-04	2014-05-07	Bio-Energy Corporation	Polyesterpolyol
CN100460441C (zh) *	2006-09-25	2009-02-11	南开大学	生物可降解星型结构聚乙丙交酯载药微球及其制备方法
MX2009006653A (es)	2006-12-18	2009-07-02	Takeda Pharmaceutical	Composicion de liberacion prolongada y metodo para producirla.
PE20090387A1 (es)	2007-05-24	2009-04-28	Novartis Ag	Formulacion de pasireotida
EP2251006B1 (de)	2008-02-22	2017-07-19	Toray Industries, Inc.	Mikropartikel und pharmazeutische zusammensetzungen daraus
EP2213307A1 (de)	2009-02-03	2010-08-04	Novartis AG	Injizierbare Depotformulierungen
EP2172189A1 (de)	2008-10-01	2010-04-07	Novartis AG	Pharmazeutische Zusammensetzungen
US20100086597A1 (en) *	2008-10-06	2010-04-08	Oakwood Laboratories LLC	Microspheres for the sustained release of octreotide with a low initial burst
US20100086596A1 (en) *	2008-10-06	2010-04-08	Oakwood Laboratories LLC	Microspheres for releasing an octreotide compound without an initial time lag
CN102282194B (zh) *	2009-01-16	2015-02-25	生物基础塑料开发有限公司	聚乳酸树脂组合物和聚乳酸树脂用添加剂
JP5362400B2 (ja) *	2009-03-17	2013-12-11	株式会社クレハ	低溶融粘度化ポリグリコール酸の製造方法
CA2796756A1 (en)	2010-04-22	2011-10-27	Intra-Cellular Therapies, Inc.	Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
GB201016436D0 (en)	2010-09-30	2010-11-17	Q Chip Ltd	Method of making solid beads
GB201016433D0 (en)	2010-09-30	2010-11-17	Q Chip Ltd	Apparatus and method for making solid beads
EP2455414A1 (de) *	2010-11-17	2012-05-23	Evonik Röhm GmbH	Verfahren zur Herstellung von hochmolekularen, resorbierbaren Polyestern, die mit dem Verfahren herstellbaren hochmolekularen resorbierbaren Polyester und deren Verwendung
EP2455415A1 (de) *	2010-11-17	2012-05-23	Evonik Röhm GmbH	Verfahren zur Herstellung von niedermolekularen, resorbierbaren Polyestern, die mit dem Verfahren herstellbaren niedermolekularen resorbierbaren Polyester und deren Verwendung
WO2012083026A1 (en) *	2010-12-15	2012-06-21	Evonik Degussa Corporation	Branched polyol polyesters, blends and pharmaceutical formulations comprising same
KR20140146192A (ko)	2012-04-14	2014-12-24	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
JP2014095067A (ja) *	2012-10-11	2014-05-22	Ricoh Co Ltd	高分子化合物、包接化合物、シート、および、水分散体
US9708322B2 (en)	2013-03-15	2017-07-18	Intra-Cellular Therapies, Inc.	Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
TW201605488A (zh) *	2013-10-15	2016-02-16	大塚製藥股份有限公司	用以預防及／或治療多囊腎病之藥物
KR102373288B1 (ko)	2013-12-03	2022-03-10	인트라-셀룰라 써래피스, 인코퍼레이티드.	신규한 방법
CA2944755A1 (en)	2014-04-04	2015-10-08	Intra-Cellular Therapies, Inc.	Organic compounds
US10077267B2 (en)	2014-04-04	2018-09-18	Intra-Cellular Therapies, Inc.	Organic compounds
WO2015191554A1 (en)	2014-06-09	2015-12-17	Intra-Cellular Therapies, Inc.	Compounds and methods of use to treat schizophrenia
JP2016186055A (ja) *	2015-03-27	2016-10-27	株式会社クレハ	ポリグリコール酸組成物および一時目止め材
PL3838274T3 (pl)	2016-01-26	2024-04-02	Intra-Cellular Therapies, Inc.	Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
DK3407889T3 (da)	2016-03-25	2021-08-09	Intra Cellular Therapies Inc	Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
EP3525763B1 (de)	2016-10-12	2025-03-05	Intra-Cellular Therapies, Inc.	Amorphe feste dispersionen
EP3562484B1 (de)	2016-12-29	2021-08-25	Intra-Cellular Therapies, Inc.	Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalinderivate zur behandlung von erkrankungen des zns
WO2018126140A1 (en)	2016-12-29	2018-07-05	Intra-Cellular Therapies, Inc.	Organic compounds
RU2767410C2 (ru)	2017-03-24	2022-03-17	Интра-Селлулар Терапиз, Инк.	Новые композиции и способы
JP7261218B2 (ja)	2017-07-07	2023-04-19	ステパンカンパニー	ポリウレタン用途のための低粘度ポリオール
WO2019023062A1 (en)	2017-07-26	2019-01-31	Intra-Cellular Therapies, Inc.	ORGANIC COMPOUNDS
EP3658144B1 (de)	2017-07-26	2022-01-26	Intra-Cellular Therapies, Inc.	Pyridopyrroloquinoxalinverbindungen, deren zusammensetzungen und verwendungen in therapie
US20200353419A1 (en)	2017-11-22	2020-11-12	Dauntless 1, Inc.	Membrane emulsification device for microsphere creation
WO2019104225A1 (en)	2017-11-22	2019-05-31	Dauntless 2, Inc.	Therapeutic compound formulations
WO2019178484A1 (en)	2018-03-16	2019-09-19	Intra-Cellular Therapies, Inc.	Novel methods
CN112040940A (zh)	2018-03-23	2020-12-04	细胞内治疗公司	有机化合物
US20210008065A1 (en)	2018-03-23	2021-01-14	Intra-Cellular Therapies, Inc.	Organic compounds
EP3801527B1 (de)	2018-06-08	2025-02-19	Intra-Cellular Therapies, Inc.	Anellierte gamma-carboline zur akutbehandlung von angst oder depression
WO2020005842A1 (en)	2018-06-25	2020-01-02	Dauntless 2, Inc.	Membrane emulsification device with impeller for microsphere creation
US12144808B2 (en)	2018-08-29	2024-11-19	Intra-Cellular Therapies, Inc.	Compositions and methods
BR112021003655A2 (pt)	2018-08-31	2021-05-18	Intra-Cellular Therapies, Inc.	métodos novos
WO2020047408A1 (en)	2018-08-31	2020-03-05	Intra-Cellular Therapies, Inc.	Novel methods
WO2020131899A1 (en)	2018-12-17	2020-06-25	Intra-Cellular Therapies, Inc.	Organic compound
WO2021007245A1 (en)	2019-07-07	2021-01-14	Intra-Cellular Therapies, Inc.	Novel methods
EP4072554A4 (de)	2019-12-11	2023-12-20	Intra-Cellular Therapies, Inc.	Organische verbindung
US12414948B2 (en)	2022-05-18	2025-09-16	Intra-Cellular Therapies, Inc.	Methods
WO2024145659A1 (en)	2022-12-30	2024-07-04	Intra-Cellular Therapies, Inc.	Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor
WO2026011166A1 (en)	2024-07-03	2026-01-08	Intra-Cellular Therapies, Inc.	Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor
WO2026011136A1 (en)	2024-07-03	2026-01-08	Intra-Cellular Therapies, Inc.	Organic compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1020324B (de) *	1954-12-17	1957-12-05	Boehringer Sohn Ingelheim	Verfahren zur Herstellung von esterartigen Milchsaeurederivaten mit definierter Kettenlaenge und endstaendiger Ester-, Amid- oder Nitrilgruppe
FR1584732A (de) *	1968-03-13	1970-01-02
FR1590574A (de) *	1968-05-09	1970-04-20
US3887699A (en) *	1969-03-24	1975-06-03	Seymour Yolles	Biodegradable polymeric article for dispensing drugs
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
IE35855B1 (en) *	1970-12-18	1976-06-09	Ethicon Inc	Absorbable copolymer suture
US3963699A (en) *	1974-01-10	1976-06-15	The Procter & Gamble Company	Synthesis of higher polyol fatty acid polyesters
NO142306C (no) *	1975-04-18	1980-07-30	Tate & Lyle Ltd	Fremgangsmaate til rensing av et fast stoff i form av et omestringsprodukt frembrakt ved reaksjon mellom sukrose og minst ett fettsyretriglycerid
US4328204A (en) *	1977-03-02	1982-05-04	Ethicon, Inc.	Absorbable polymer-drug compounds and method for making same
DE2856901D2 (de) *	1977-06-07	1980-11-13	Garching Instrumente	Form of implant medicament and preparation process
US4130639A (en) *	1977-09-28	1978-12-19	Ethicon, Inc.	Absorbable pharmaceutical compositions based on isomorphic copolyoxalates
US4165432A (en) *	1977-10-18	1979-08-21	Olin Corporation	Peroxy di-ester polyols
DE2824112A1 (de) *	1978-06-01	1979-12-06	Garching Instrumente	Mikropellets, verfahren zu ihrer herstellung und deren verwendung
US4273920A (en) *	1979-09-12	1981-06-16	Eli Lilly And Company	Polymerization process and product
US4334061A (en) *	1979-10-29	1982-06-08	Ethyl Corporation	Process for recovery of polyol fatty acid polyesters
DE3045135A1 (de) *	1980-11-29	1982-06-09	Sandoz-Patent-GmbH, 7850 Lörrach	Pharmazeutische kompositionen enthaltende bioabbaubare polymere
IE52535B1 (en) *	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
EP0092918B1 (de) *	1982-04-22	1988-10-19	Imperial Chemical Industries Plc	Mittel mit verzögerter Freigabe
US4452973A (en) *	1982-11-12	1984-06-05	American Cyanamid Company	Poly(glycolic acid)/poly(oxyethylene) triblock copolymers and method of manufacturing the same
FR2537980B1 (fr) *	1982-12-17	1986-12-19	Sandoz Sa	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation

1983
- 1983-08-26 CH CH4671/83A patent/CH656884A5/de not_active IP Right Cessation
1984
- 1984-08-20 NL NLAANVRAGE8402547,A patent/NL190415C/xx not_active IP Right Cessation
- 1984-08-21 HU HU843146A patent/HU195426B/hu unknown
- 1984-08-21 FR FR8413111A patent/FR2551072B1/fr not_active Expired
- 1984-08-22 GB GB08421273A patent/GB2145422B/en not_active Expired
- 1984-08-22 BE BE1/11073A patent/BE900406A/fr not_active IP Right Cessation
- 1984-08-22 DE DE3430852A patent/DE3430852C2/de not_active Expired - Lifetime
- 1984-08-23 GR GR80184A patent/GR80184B/el unknown
- 1984-08-24 IT IT22413/84A patent/IT1176629B/it active Protection Beyond IP Right Term
- 1984-08-24 IL IL72763A patent/IL72763A/xx not_active IP Right Cessation
- 1984-08-24 ZA ZA846634A patent/ZA846634B/xx unknown
- 1984-08-24 SE SE8404225A patent/SE462098B/sv not_active IP Right Cessation
- 1984-08-24 AT AT0271384A patent/AT395584B/de active
- 1984-08-24 LU LU85514A patent/LU85514A1/fr unknown
- 1984-08-24 NZ NZ209335A patent/NZ209335A/xx unknown
- 1984-08-24 AU AU32348/84A patent/AU575066B2/en not_active Expired
- 1984-08-24 ES ES535399A patent/ES8706750A1/es not_active Expired
- 1984-08-24 PH PH31143A patent/PH23556A/en unknown
- 1984-08-24 JP JP59177375A patent/JPH0819226B2/ja not_active Expired - Lifetime
- 1984-08-24 PT PT79129A patent/PT79129B/pt unknown
- 1984-08-24 IE IE217184A patent/IE58818B1/xx not_active IP Right Cessation
- 1984-08-24 DK DK198404072A patent/DK173556B1/da not_active IP Right Cessation
1987
- 1987-09-24 MY MYPI87001920A patent/MY101861A/en unknown
1990
- 1990-07-11 SG SG535/90A patent/SG53590G/en unknown
- 1990-08-30 HK HK673/90A patent/HK67390A/xx not_active IP Right Cessation
1991
- 1991-03-22 CY CY1556A patent/CY1556A/en unknown
1992
- 1992-02-11 US US07/834,018 patent/US5922682A/en not_active Expired - Lifetime
1995
- 1995-06-06 US US08/471,304 patent/US5922338A/en not_active Expired - Lifetime
1996
- 1996-06-06 NL NL960014C patent/NL960014I1/nl unknown

Also Published As

Publication number	Publication date
IE58818B1 (en)	1993-11-17
NL190415B (nl)	1993-09-16
BE900406A (fr)	1985-02-22
GB8421273D0 (en)	1984-09-26
DK173556B1 (da)	2001-03-12
DE3430852A1 (de)	1985-03-14
JPH0819226B2 (ja)	1996-02-28
NL190415C (nl)	1994-02-16
US5922338A (en)	1999-07-13
NZ209335A (en)	1988-08-30
NL960014I1 (nl)	1996-10-01
US5922682A (en)	1999-07-13
IE842171L (en)	1985-02-26
PT79129B (en)	1986-07-17
IL72763A0 (en)	1984-11-30
AT395584B (de)	1993-01-25
AU575066B2 (en)	1988-07-21
CY1556A (en)	1991-03-22
ATA271384A (de)	1992-06-15
SE8404225L (sv)	1985-02-27
IL72763A (en)	1988-02-29
CH656884A5 (de)	1986-07-31
MY101861A (en)	1992-01-31
IT8422413A0 (it)	1984-08-24
DK407284A (da)	1985-02-27
SE462098B (sv)	1990-05-07
DE3430852C2 (de)	2003-08-14
NL8402547A (nl)	1985-03-18
GB2145422A (en)	1985-03-27
FR2551072B1 (fr)	1988-01-15
HK67390A (en)	1990-09-07
HUT38265A (en)	1986-05-28
IT1176629B (it)	1987-08-18
GR80184B (en)	1985-01-02
HU195426B (en)	1988-05-30
SE8404225D0 (sv)	1984-08-24
JPS6076531A (ja)	1985-05-01
SG53590G (en)	1990-10-26
ES535399A0 (es)	1987-06-16
FR2551072A1 (fr)	1985-03-01
ZA846634B (en)	1986-04-30
DK407284D0 (da)	1984-08-24
PT79129A (en)	1984-09-01
PH23556A (en)	1989-08-25
AU3234884A (en)	1985-02-28
GB2145422B (en)	1987-08-26
ES8706750A1 (es)	1987-06-16

Publication	Publication Date	Title
LU85514A1 (fr)	1985-04-24	Nouveaux esters de polyols,leur preparation et leur utilisation
EP0520888B1 (de)	2001-09-19	Nanopartikel aus Polyoxyäthylen-Polymilchsäure Blockcopolymeren
EP0646001B1 (de)	1997-09-17	Mikrokügeln aus bioresorbierbarem polymer ohne tensid, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2537980A1 (fr)	1984-06-22	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
EP0179023B1 (de)	1991-01-23	Durch Mikroorganismen abbaubares Polypeptid und seine Verwendung für die fortschreitende Abgabe von Medikamenten
BE1004486A3 (fr)	1992-12-01	Formulations a liberation prolongee de peptides solubles dans l'eau.
EP0585151B1 (de)	2000-01-05	Verfahren zum Herstellen von Microkugeln für die verzögerte Verabreichung des LHRH-Hormons und dessen Analoga, Microkugeln und so erhaltene Zusammensetzungen
CN101910274B (zh)	2014-07-30	含紫杉烷的两亲嵌段共聚物胶束组合物及其制备方法
FR2741628A1 (fr)	1997-05-30	Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
WO2003099260A1 (fr)	2003-12-04	Procede de production d'une preparation pharmaceutique a base de micelles polymere contenant un medicament a injecter
EP0150184A1 (de)	1985-08-07	In vivo abbaubares polypeptid und dessen anwendung zur verzögerten freigabe von medikamenten
Miao et al.	2006	Study on drug release behaviors of poly-α, β-[N-(2-hydroxyethyl)-l-aspartamide]-g-poly (ε-caprolactone) nano-and microparticles
CN1144677A (zh)	1997-03-12	黄烷酮木脂素制剂，其制备方法及含该制剂的药物
EP0591331B1 (de)	1996-03-13	Verfahren zur herstellung von nanopartikeln
FR3122571A1 (fr)	2022-11-11	Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles
WO2007136134A1 (ja)	2007-11-29	疎水性薬物内包ポリマーミセルの製造方法
BE898430A (fr)	1984-06-12	Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation.
BE1001687A5 (fr)	1990-02-06	Composition a base de polyesters pour la liberation controlee de substances medicamenteuses.
CN1939316A (zh)	2007-04-04	含阿霉素的微球,其用途及其制备方法
KR930002707B1 (ko)	1993-04-09	폴리올 에스테르의 제조방법
CN121343141A (zh)	2026-01-16	一种可吸收聚合物粉末及其纯化方法